Levi & Korsinsky Alerts Investors of Class Action Against Unicycive Therapeutics

In a recent announcement, Levi & Korsinsky, LLP, a prominent law firm known for representing investors, has notified shareholders of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) about a class action lawsuit targeting the company. The lawsuit is focused on alleged securities fraud that occurred between March 29, 2024, and June 27, 2025, during which investors may have faced significant losses.

Case Overview

The case filed against Unicycive Therapeutics claims that the company's executives made misleading statements and concealed critical information regarding the company's manufacturing capabilities and regulatory compliance with the FDA. Specifically, it is alleged that:

1. The readiness of Unicycive to meet FDA manufacturing standards was exaggerated.
2. The prospects for the company's new drug application for oxylanthanum carbonate were misrepresented.
3. Due to these misleading statements, investors were unable to make informed decisions, leading to financial losses.

The lawsuit aims to provide recovery for those affected by these allegations. Investors are encouraged to review their options carefully.

Important Deadlines

For those who have experienced financial losses during the relevant time frame, it is vital to act quickly. The deadline to request appointment as lead plaintiff in the case is October 14, 2025. However, it is important to note that participating in any recovery does not require one to serve as the lead plaintiff.

Cost-Free Participation

One notable aspect of this class action lawsuit is that affected investors can be eligible for compensation without incurring any direct out-of-pocket expenses. This means potential plaintiffs can participate at no financial risk, as there is no obligation or cost to join the lawsuit.

Why Choose Levi & Korsinsky?

With over 20 years of experience, Levi & Korsinsky has built a solid reputation in the field of securities litigation. They have successfully secured hundreds of millions of dollars for shareholders while focusing on high-stakes litigation. Their team comprises over 70 professionals, ready to assist clients in navigating complex legal scenarios efficiently.

For the past several years, the firm has consistently ranked as one of the top securities litigation firms in the United States, according to ISS Securities Class Action Services. This established track record gives potential claimants confidence in their pursuit of losses associated with Unicycive Therapeutics.

How to Get Involved

Investors interested in learning more about this class action lawsuit can reach out directly to Levi & Korsinsky for assistance. They can contact Joseph E. Levi, Esq. via email at [email protected] or by phone at (212) 363-7500 for further guidance or to discuss the specifics of their situation.

Conclusion

As Unicycive Therapeutics continues to navigate the challenges posed by this lawsuit, it is imperative for affected investors to understand their rights and options. The deadline for participation is fast approaching, making swift action essential for those impacted during the outlined period. Levi & Korsinsky stands ready to support these investors in their quest for justice and recovery.